Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Motesanib with Chemotherapy and/or Panitumumab in Advanced NSCLC
NCT00094835Phase 2Completed
- Sponsor
- Amgen
- Start
- Jan 2005
- Primary completion
- Mar 2007
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of motesanib in non-small cell lung cancer (NSCLC), sponsored by Amgen. Started Jan 2005; status: completed.
02
Drugs
motesanib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00094835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00094835.